FIG 3.

Examining the durability of virus-specific antibody after depletion of B cells. (A to F) Virus-specific antibody responses were assessed in the serum of rituximab-treated (red) and PBS-treated (black) hCD20tg mice immune to LCMV (A), influenza (B and D), or VSV (C and E). (A to C) Virus-specific IgG was measured by ELISA. (D) Hemagglutination inhibition (HAI) titers of influenza immune mice. (E) VSV neutralization titers in VSV immune mice. Treatment initiation and period are indicated by vertical dotted line and gray shading, respectively. Horizontal dotted line indicates the limit of detection. Data (mean and SEM) from a representative experiment (n = 4 to 6 mice per group) are shown. (F) Combined estimated half-life of virus-specific antibody responses measured in panels A to E are shown for both phases of the biphasic decline.